Dwight C. Macero, MS, PA-C, discusses the role that advanced practice providers play in managing the side effects of hematologic treatments.
Therapies to treat hematologic malignancies (including cytotoxic chemotherapies, targeted therapies, immunotherapies, radiation, and hematopoietic cell transplantation [HCT]) continue to improve outcomes and extend the lives of our patients. However, nearly all patients will experience some side effects of these life-saving treatments. Treatment-related adverse events (AEs) affect patients’ overall health, including quality of life, and may lead to treatment delays or interruptions that can affect clinical outcomes.
Early identification is key to managing AEs. Establishing rapport and maintaining open communication with our patients is of the utmost importance for being clued in early to any potential side effects, allowing for easier management and lessening severity. As advanced practice providers (APPs), our clinical knowledge and experience, together with our close relationships with patients, put us on the frontline of identifying and managing AEs.
Read more on Ash Clinical News >>>